• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

In survival mode, Exicure cuts to the bone — pausing all R&D and chopping headcount by 66%

cafead

Administrator
Staff member
  • cafead   Sep 27, 2022 at 10:32: AM
via The drastic restructuring that Exicure undertook at the end of last year couldn’t save the biotech after all.

In fact, Exicure — whose take on gene expression once drew the backing of Bill Gates and a slate of tech investors — is going for another round of layoffs, this time cutting to the bone with 66% of the remaining staffers being let go, while halting all R&D activities and looking to divest its entire pipeline.

article source